A plethora of carbapenem resistance in Acinetobacter baumannii: no end to a long insidious genetic journey

References

• Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci. 2018;25(3):586–96.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358(12):1271–81.
   PubMed Web of Science ®Google Scholar
• Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist. 2018;11:2277–99.
   PubMed Web of Science ®Google Scholar
• Cabral MP, Soares NC, Aranda J, Parreira JR, Rumbo C, Poza M, et al. Proteomic and functional analyses reveal a unique lifestyle for Acinetobacter baumannii biofilms and a key role for histidine metabolism. J Proteome Res. 2011;10(8):3399–417.
   PubMed Web of Science ®Google Scholar
• Colquhoun JM, Rather PN. Insights into mechanisms of biofilm formation in Acinetobacter baumannii and implications for uropathogenesis. Front Cell Infect Microbiol. 2020;10(253):1–18.
   PubMedGoogle Scholar
• Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents. 2008;32(2):106–19.
   PubMed Web of Science ®Google Scholar
• Joly-Guillou M-L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11(11):868–73.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37(2):130–55.
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–84.
   PubMed Web of Science ®Google Scholar
• Lin M-F, Lan C-Y. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases. 2014;2(12):787–814.
   PubMed Web of Science ®Google Scholar
• Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:1–24.
   PubMed Web of Science ®Google Scholar
• https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
   Google Scholar
• Amiri S, Hammami S, Amoura K, Dekhil M, Boubaker IB-B. Characterization of carbapenem resistant Acinetobacter baumannii isolated from intensive care units in two teaching hospitals from Algeria and Tunisia. Pan Afr Med. 2017;28(1):19–27.
   Google Scholar
• World Health Organization. Implementation manual to prevent and control the spread of carbapenem-resistant organisms at the national and health care facility level: interim practical manual supporting implementation of the Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. World Health Organization, 2019.
   Google Scholar
• Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005;11(1):22–9.
   PubMed Web of Science ®Google Scholar
• Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010;2(3):291–304.
   PubMedGoogle Scholar
• Poirel L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life. 2011;63(12):1061–7.
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35(3):219–26.
   PubMed Web of Science ®Google Scholar
• Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51(1):79–84.
   PubMed Web of Science ®Google Scholar
• Lowings M, Ehlers MM, Kock MM. Acinetobater baumannii: a superbug. The battle against microbial pathogens: basic science, technological advances and educational programs. Badajoz: Formatex Research Center. 2015;587–97.
   Google Scholar
• Kattan J, Villegas M, Quinn J. New developments in carbapenems. Clin Microbiol Infect. 2008;14(12):1102–11.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.
   PubMed Web of Science ®Google Scholar
• Towner K. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009;73(4):355–63.
   PubMed Web of Science ®Google Scholar
• Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011;52(6):879–91.
   PubMed Web of Science ®Google Scholar
• Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004;38(9):1449–59.
   PubMed Web of Science ®Google Scholar
• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–51.
   PubMed Web of Science ®Google Scholar
• Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(2):233–8.
   PubMed Web of Science ®Google Scholar
• Da Silva GJ, Domingues S. Insights on the horizontal gene transfer of carbapenemase determinants in the opportunistic pathogen. Acinetobacter baumannii. Microorganisms. 2016;4(3):29.
   Google Scholar
• Wachino J-i, Jin W, Kimura K, Arakawa Y. Intercellular transfer of chromosomal antimicrobial resistance genes between Acinetobacter baumannii strains mediated by prophages. Antimicrob Agents Chemother. 2019;63(8):e00334.
   PubMed Web of Science ®Google Scholar
• Rumbo C, Fernández-Moreira E, Merino M, Poza M, Mendez JA, Soares NC, Mosquera A, Chaves F, Bou G. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–90.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Mondal A, Mitra S, Basu S. Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles. J Antimicrob Chemother. 2017;72(8):2201–7.
   PubMed Web of Science ®Google Scholar
• Krahn T, Wibberg D, Maus I, Winkler A, Bontron S, Sczyrba A, Nordmann P, Pühler A, Poirel L, Schlüter A, et al. Intraspecies transfer of the chromosomal Acinetobacter baumannii blaNDM-1 carbapenemase gene. Antimicrob Agents Chemother. 2016;60(5):3032–40.
   PubMed Web of Science ®Google Scholar
• Bontron S, Nordmann P, Poirel L. Transposition of Tn125 encoding the NDM-1 carbapenemase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(12):7245–51.
   PubMed Web of Science ®Google Scholar
• López-Leal G, Santamaria RI, Cevallos MÁ, Gonzalez V, Castillo-Ramírez S. Prophages encode antibiotic resistance genes in Acinetobacter baumannii. Microb Drug Resist. 2020:26(10):1275–1277.
   PubMedGoogle Scholar
• Badawy S, Pajunen MI, Haiko J, Baka ZAM, Abou-Dobara MI, El-Sayed AKA, Skurnik M. Identification and functional analysis of temperate siphoviridae bacteriophages of Acinetobacter baumannii. Viruses. 2020;12(6):604:1–20.
   Web of Science ®Google Scholar
• Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob. 2003;51(3):565–74.
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12(9):826–36.
   PubMed Web of Science ®Google Scholar
• Thomson KS. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues . J Clin Microbiol. 2010;48(4):1019–25.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161–82.
   PubMed Web of Science ®Google Scholar
• Walsh T. The emergence and implications of metallo‐β‐lactamases in Gram‐negative bacteria. CMI. 2005;11:2–9.
   Google Scholar
• Amin M, Navidifar T, Shooshtari FS, Goodarzi H. Association of the genes encoding Metallo-β-Lactamase with the presence of integrons among multidrug-resistant clinical isolates of Acinetobacter baumannii. Infect Drug Resist. 2019;12:1171–80.
   PubMed Web of Science ®Google Scholar
• Abouelfetouh A, Torky AS, Aboulmagd E. Phenotypic and genotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from Egypt. Antimicrob Resist Infect Control. 2019;8(1):185
   PubMed Web of Science ®Google Scholar
• Alkasaby NM, El Sayed Zaki M. Molecular study of Acinetobacter baumannii isolates for Metallo-β-lactamases and extended-spectrum-β-lactamases genes in intensive care unit, Mansoura University Hospital, Egypt. Int J Microbiol. 2017; 2017:3925868.
   PubMed Web of Science ®Google Scholar
• Aksoy MD, Çavuşlu Ş, Tuğrul HM. Investigation of metallo beta lactamases and oxacilinases in carbapenem resistant Acinetobacter baumannii strains isolated from inpatients. Balkan Med J. 2015;32(1):79–83.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR. Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. Antimicrob Agents Chemother. 2007;51(7):2611–4.
   PubMed Web of Science ®Google Scholar
• Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. Class D β-lactamases: are they all carbapenemases? Antimicrob Agents Chemother. 2014;58(4):2119–25.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2010;54(1):24–38.
   PubMed Web of Science ®Google Scholar
• Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev anti Infect Ther. 2013;11(4):395–409.
   PubMed Web of Science ®Google Scholar
• Brown S, Amyes S. OXA β-lactamases in Acinetobacter: the story so far. J Antimicrob. 2005;57(1):1–3.
   PubMed Web of Science ®Google Scholar
• Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. J Antimicrob Chemother. 2006;57(3):373–83.
   PubMed Web of Science ®Google Scholar
• Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii . Antimicrob Agents Chemother. 2001;45(2):583–8.
   PubMed Web of Science ®Google Scholar
• Donald HM, Scaife W, Amyes SG, Young H-K. Sequence Analysis of ARI-1, a Novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother. 2000;44(1):196–9.
   PubMed Web of Science ®Google Scholar
• Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain . Antimicrob Agents Chemother. 2000;44(6):1556–61.
   PubMed Web of Science ®Google Scholar
• Brown S, Young H, Amyes S. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. CMI. 2005;11(1):15–23.
   Google Scholar
• Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50(4):1442–8.
   PubMed Web of Science ®Google Scholar
• Marqué S, Poirel L, Héritier C, Brisse S, Blasco MD, Filip R, Coman G, Naas T, Nordmann P. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol. 2005;43(9):4885–8.
   PubMed Web of Science ®Google Scholar
• Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009;53(12):5035–8.
   PubMed Web of Science ®Google Scholar
• Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(5):2121–6.
   PubMed Web of Science ®Google Scholar
• Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258(1):72–7.
   PubMed Web of Science ®Google Scholar
• Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. Prevalence of IS(Aba1) in epidemiologically unrelated Acinetobacter baumannii clinical isolates. FEMS Microbiol Lett. 2007;274(1):63–6.
   PubMed Web of Science ®Google Scholar
• Naas T, Nordmann P. OXA-Type -Lactamases. Curr Pharm Des. 1999;5(11):865–80.
   PubMed Web of Science ®Google Scholar
• Al-Arfaj AA, Ibrahim AS, Somily AM, Al-Salamah AA. Genetic basis of carbapenem resistance in Acinetobacter clinical isolates in Saudi Arabia. Afr J Biotechnol. 2011;10(64):14186–96.
   Google Scholar
• Elabd FM, Al-Ayed MS, Asaad AM, Alsareii SA, Qureshi MA, Musa HA-A. Molecular characterization of oxacillinases among carbapenem-resistant Acinetobacter baumannii nosocomial isolates in a Saudi hospital. J Infect Public Health. 2015;8(3):242–7.
   PubMed Web of Science ®Google Scholar
• Al-Agamy MH, Shibl AM, Ali MS, Khubnani H, Radwan HH, Livermore DM. Distribution of β-lactamases in carbapenem-non-susceptible Acinetobacter baumannii in Riyadh, Saudi Arabia. J Glob Antimicrob Resist. 2014;2(1):17–21.
   PubMed Web of Science ®Google Scholar
• Amr GE, Abdel Razek G. Characterization of carbapenem resistant Acinetobacter baumannii causing ventilator associated pneumonia in ICUs of Zagazig University Hospitals, Egypt. Int.J.Curr.Microbiol.App.Sci. 2016;5(12):660–71.
   Google Scholar
• Carvalho KR, Carvalho-Assef APDA, Peirano G, dos Santos LCG, Pereira MJF, Asensi MD. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents. 2009;34(1):25–8.
   PubMed Web of Science ®Google Scholar
• Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-β-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68(3):550–3.
   PubMed Web of Science ®Google Scholar
• Lean S-S, Suhaili Z, Ismail S, Rahman NIA, Othman N, Abdullah FH, Jusoh Z, Yeo CC, Thong K-L. Prevalence and genetic characterization of carbapenem-and polymyxin-resistant Acinetobacter baumannii isolated from a tertiary hospital in Terengganu. Malaysia. Int Scho Res Not. 2014;2014:1–9.
   Google Scholar
• Sohrabi N, Farajnia S, Akhi MT, Nahaei MR, Naghili B, Peymani A, Amiri Z, Rezaee MA, Saeedi N. Prevalence of OXA-type β-lactamases among Acinetobacter baumannii isolates from Northwest of Iran. Microb Drug Resist. 2012;18(4):385–9.
   PubMed Web of Science ®Google Scholar
• Savari M, Ekrami A, Shoja S, Bahador A. Plasmid borne Carbapenem-Hydrolyzing Class D β-Lactamases (CHDLs) and AdeABC efflux pump conferring carbapenem-tigecycline resistance among Acinetobacter baumannii isolates harboring TnAbaRs. Microb Pathog. 2017;104:310–7.
   PubMed Web of Science ®Google Scholar
• Al-Sweih N, Al-Hubail M, Rotimi V. Three distinct clones of carbapenem-resistant Acinetobacter baumannii with high diversity of carbapenemases isolated from patients in two hospitals in Kuwait. J Infect Public Health. 2012;5(1):102–8.
   PubMedGoogle Scholar
• Chang Y, Luan G, Xu Y, Wang Y, Shen M, Zhang C, et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol. 2015;6:910.
   PubMed Web of Science ®Google Scholar
• Khorsi K, Messai Y, Hamidi M, Ammari H, Bakour R. High prevalence of multidrug-resistance in Acinetobacter baumannii and dissemination of carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like and blaNDM-1 in Algiers hospitals. Asian Pac J Trop Med. 2015;8(6):438–46.
   PubMed Web of Science ®Google Scholar
• Cherkaoui A, Emonet S, Renzi G, Schrenzel J. Characteristics of multidrug-resistant Acinetobacter baumannii strains isolated in Geneva during colonization or infection. Ann Clin Microbiol Antimicrob. 2015;14(1):1–7.
   PubMedGoogle Scholar
• Nowak P, Paluchowska P, Budak A. Distribution of blaOXA genes among carbapenem-resistant Acinetobacter baumannii nosocomial strains in Poland. New Microbiol. 2012;35(3):317–25.
   PubMed Web of Science ®Google Scholar
• Gribun A, Nitzan Y, Pechatnikov I, Hershkovits G, Katcoff DJ. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii. Curr Microbiol. 2003;47(5):434–43.
   PubMed Web of Science ®Google Scholar
• Vila J, Martí S, Sanchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2007;59(6):1210–5.
   PubMed Web of Science ®Google Scholar
• Lin M-F, Lin Y-Y, Tu C-C, Lan C-Y. Distribution of different efflux pump genes in clinical isolates of multidrug-resistant Acinetobacter baumannii and their correlation with antimicrobial resistance. J Microbiol Immunol. 2017;50(2):224–31.
   Web of Science ®Google Scholar
• Poole K. Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotechnol. 2002;3(2):77–98.
   PubMedGoogle Scholar
• Bratu S, Landman D, Martin DA, Georgescu C, Quale J. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother. 2008;52(9):2999–3005.
   PubMed Web of Science ®Google Scholar
• Fernández L, Hancock RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25(4):661–81.
   PubMed Web of Science ®Google Scholar
• Smani Y, Fàbrega A, Roca I, Sánchez-Encinales V, Vila J, Pachón J. Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58(3):1806–8.
   PubMed Web of Science ®Google Scholar
• Walzer G, Rosenberg E, Ron EZ. The Acinetobacter outer membrane protein A (OmpA) is a secreted emulsifier. Environ Microbiol. 2006;8(6):1026–32.
   PubMed Web of Science ®Google Scholar
• Dupont M, Pagès J-M, Lafitte D, Siroy A, Bollet C. Identification of an OprD Homologue in Acinetobacter baumannii. J Proteome Res. 2005;4(6):2386–90.
   PubMed Web of Science ®Google Scholar
• del Mar Tomás M, Beceiro A, Pérez A, Velasco D, Moure R, Villanueva R, Martínez-Beltrán J, Bou G. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(12):5172–5.
   PubMed Web of Science ®Google Scholar
• Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins . Antimicrob Agents Chemother. 2005;49(4):1432–40.
   PubMed Web of Science ®Google Scholar
• Siroy A, Cosette P, Seyer D, Lemaître-Guillier C, Vallenet D, Van Dorsselaer A, Boyer-Mariotte S, Jouenne T, Dé E. Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. J Proteome Res. 2006;5(12):3385–98.
   PubMed Web of Science ®Google Scholar
• Siroy A, Molle V, Lemaître-Guillier C, Vallenet D, Pestel-Caron M, Cozzone AJ, Jouenne T, Dé E. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(12):4876–83.
   PubMed Web of Science ®Google Scholar
• Lin L, Ling B-D, Li X-Z. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents. 2009;33(1):27–32.
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19(2):382–402.
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006;4(8):629–36.
   PubMed Web of Science ®Google Scholar
• Rumbo C, Gato E, López M, Ruiz de Alegría C, Fernández-Cuenca F, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Spanish Network for Research in Infectious Diseases(REIPI), et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(11):5247–57.
   PubMed Web of Science ®Google Scholar
• Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55(3):947–53.
   PubMed Web of Science ®Google Scholar
• Alvarez-Ortega C, Olivares J, Martínez JL. RND multidrug efflux pumps: what are they good for? Front Microbiol. 2013;4:7
   PubMed Web of Science ®Google Scholar
• Xing L, Barnie PA, Su Z, Xu H. Development of efflux pumps and inhibitors (EPIs) in A. baumanii. J Clin Microbiol. 2014;:3:135:1–6.
   Google Scholar
• Chu YW, Chau SL, Houang ET. Presence of active efflux systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic DNA groups. J Med Microbiol. 2006;55(Pt 4):477–8.
   PubMed Web of Science ®Google Scholar
• Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta. 2009;1794(5):769–81.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Structure and mechanism of RND-type multidrug efflux pumps. Adv Enzymol Relat Areas Mol Biol. 2011;77:1–60.
   PubMedGoogle Scholar
• Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother. 2004;48(9):3298–304.
   PubMed Web of Science ®Google Scholar
• Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii-the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol. 2008;46(3):257–67.
   PubMed Web of Science ®Google Scholar
• Yoon E-J, Courvalin P, Grillot-Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother. 2013;57(7):2989–95.
   PubMed Web of Science ®Google Scholar
• Cortez-Cordova J, Kumar A. Activity of the efflux pump inhibitor phenylalanine-arginine β-naphthylamide against the AdeFGH pump of Acinetobacter baumannii. Int J Antimicrob Agents. 2011;37(5):420–4.
   PubMed Web of Science ®Google Scholar
• Zechini B, Versace I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov. 2009;4(1):37–50.
   PubMedGoogle Scholar
• Lee Y, Yum JH, Kim C-K, Yong D, Jeon EH, Jeong SH, et al. Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an Acinetobacter baumannii strain carrying the blaOXA-66 gene. Ann Clin Lab Sci. 2010;40(1):43–8.
   PubMed Web of Science ®Google Scholar
• Hou PF, Chen XY, Yan GF, Wang YP, Ying CM. Study of the correlation of imipenem resistance with efflux pumps AdeABC, AdeIJK, AdeDE and AbeM in clinical isolates of Acinetobacter baumannii. J Chemotherapy. 2012;58(2):152–8.
   Google Scholar
• Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother. 2008;52(2):557–62.
   PubMed Web of Science ®Google Scholar
• Rosenfeld N, Bouchier C, Courvalin P, Périchon B. Expression of the resistance-nodulation-cell division pump AdeIJK in Acinetobacter baumannii is regulated by AdeN, a TetR-type regulator. Antimicrob Agents Chemother. 2012;56(5):2504–10.
   PubMed Web of Science ®Google Scholar
• Coyne S, Rosenfeld N, Lambert T, Courvalin P, Périchon B. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(10):4389–93.
   PubMed Web of Science ®Google Scholar
• Maddocks SE, Oyston PC. Structure and function of the LysR-type transcriptional regulator (LTTR) family proteins. Microbiology (Reading). 2008;154(Pt 12):3609–23.
   PubMed Web of Science ®Google Scholar
• Chau S-L, Chu Y-W, Houang ET. Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob Agents Chemother. 2004;48(10):4054–5.
   PubMed Web of Science ®Google Scholar
• Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. J Chemotherapy. 1991;37(6):405–12.
   Google Scholar
• Piperaki E-T, Tzouvelekis L, Miriagou V, Daikos G. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–7.
   PubMed Web of Science ®Google Scholar
• Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63(1):e01110–18.
   PubMed Web of Science ®Google Scholar
• Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74(12):1315–33.
   PubMed Web of Science ®Google Scholar
• Soothill J. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 1992;37(4):258–61.
   PubMed Web of Science ®Google Scholar
• Huang G, Le S, Peng Y, Zhao Y, Yin S, Zhang L, Yao X, Tan Y, Li M, Hu F. Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii. Curr Microbiol. 2013;66(6):535–43.
   PubMed Web of Science ®Google Scholar
• Jin J, Li Z-J, Wang S-W, Wang S-M, Huang D-H, Li Y-H, Ma Y-Y, Wang J, Liu F, Chen X-D, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol. 2012;12(1):156– 8.
   PubMedGoogle Scholar
• Peng F, Mi Z, Huang Y, Yuan X, Niu W, Wang Y, Hua Y, Fan H, Bai C, Tong Y. Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates. BMC Microbiol. 2014;14(1):181
   PubMedGoogle Scholar
• Yele AB, Thawal ND, Sahu PK, Chopade BA. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arch Virol. 2012;157(8):1441–50.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954–17.
   PubMedGoogle Scholar
• Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I, Goderdzishvili M. Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front Microbiol. 2016;7:1590
   PubMed Web of Science ®Google Scholar
• Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother. 2016;60(10):5806–16.
   PubMed Web of Science ®Google Scholar
• Jeon J, Park J-H, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol. 2019;19(1):70
   PubMed Web of Science ®Google Scholar
• LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley R, Wooten D, editors. Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect Dis. 2018:1–3.
   Google Scholar
• Ghajavand H, Esfahani BN, Havaei A, Fazeli H, Jafari R, Moghim S. Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii. Res Pharm Sci. 2017;12(5):373–80.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rocha JL, Merlini AB. Combined therapy for multi-drug-resistant Acinetobacter baumannii infection–is there evidence outside the laboratory? J Med Microbiol. 2015;64(9):951–9.
   PubMedGoogle Scholar
• Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, et al. In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Open Forum Infect Dis. 2018; 5(Suppl 1): S413–S414.
   Google Scholar
• Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(1):62–4.
   PubMed Web of Science ®Google Scholar
• Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2(9):17104
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Vickers A, Woodford N, Livermore DM. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. J Antimicrob Chemother. 2017;72(6):1688–95.
   PubMed Web of Science ®Google Scholar
• Vázquez-Ucha JC, Maneiro M, Martínez-Guitián M, Buynak J, Bethel CR, Bonomo RA, et al. Activity of the β-lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii. Antimicrob Agents Chemother. 2017;61(11):e01172.
   PubMed Web of Science ®Google Scholar
• Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. Potent β-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017;61(11):e01238.
   PubMed Web of Science ®Google Scholar
• Joo H, Choi W, Kim D, Kowalik E, Hager M, Mao S, et al. editors. FSI-1671, a novel anti-Acinetobacter carbapenem; in vivo efficacy against carbapenem-resistance Gram-negative bacterial infection. Proceedings of 53rd International Interscience Conference on Antimicrob Agents Chemother, Denver, CO, USA; 2013.
   Google Scholar
• Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si Y, Abu-Taleb R, et al. SPR741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017;61(12):e01239.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Rubio-Aparicio D, Nelson K, Roberts K, Thompson P, Nation R, et al. In vitro activity of Faddi-287, a representative of a novel series of polymyxins (Pm) with reduced nephrotoxic potential. Microbe. 2016.
   Google Scholar
• Galani I, Nafplioti K, Chatzikonstantinou M, Giamarellou H, Souli M, editors. Evaluation of apramycin activity against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii.28th ECCMID, P0096. European Congress of Clin Microbiol Infec, Madrid, Spain 2018.
   Google Scholar